Clinical trial · Interventional

Probiotc Lactobacillus Crispatus-M247 (Crispact®) Supplementation in the Sterilization of High-risk Human Papilloma (HPV-HR) Viruses

Study on the Efficacy of Crispact® (Probiotic Containing Lactobacillus Crispatus M247) in the Sterilization of HPV-HR and in the Reconstitution of the Normal Vaginal Microbiota

NCT06245486CI-TRIAL-00073769unknownN/AClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

There is growing scientific interest in probiotic supplementation as a possible therapy for clearing the human papillomavirus (HPV) infection and reducing the risk of developement of cervical cancer.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Human Papillomavirus Infection	—	UNRESOLVED	—

Interventions

Interventions (2)

Intervention	Type	Mapped drug	Match
Crispact®	Dietary Supplement	—	UNRESOLVED
Placebo	Dietary Supplement	—	UNRESOLVED

Design

Arms and outcomes

Arms (4)

type
EXPERIMENTAL
label
Probiotic Young Group (Women aged 18-29 years)
description
Participants in this group will take probiotic Crispact® (20 Bld CFU/Stick of Lactobacillus crispatus M247) as 1 oral sachet per day for four months and 1 sachet in vaginal lavage for the first 10 days of treatment.
interventionNames
1. Dietary Supplement: Crispact®
type
ACTIVE_COMPARATOR
label
Control Young Group (Women aged 18-29 years)
description
Participants in this group will take Placebo as 1 oral sachet per day for four months and 1 sachet in vaginal lavage for the first 10 days of treatment.
interventionNames
1. Dietary Supplement: Placebo
type
EXPERIMENTAL
label

Eligibility

Eligibility (as posted)

Sex: Female
Minimum age: 18 Years
Maximum age: 64 Years

Show eligibility criteria text

Inclusion Criteria:

* Women able to understand and agree to participation in the study and be able to provide written informed consent to the trial.
* Women aged 25-29 years who perform screening pap smears with the result: Low- grade squamous intraepithelial lesion (LSIL) or Atypical Squamous Cells of Undetermined Significanc (ASCUS) (for which, as per the recommendation of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV)/Italian Group of Cervical Cancer. Screening (GISCI), no treatment is indicated but only follow-up with Human papillomavirus (HPV) test at 12 months.
* Women aged 18-64 who independently perform a positive High risk sub-types of HPV (HR-HPV) test outside of screening even in the presence of a negative cytology (for whom, as per the recommendation of the SICPCV, no treatment is indicated but only follow-up with HPV test at 12 months).
* Women aged 30-64 years HPV HR positive with negative cytology or with positive cytology for ASCUS or LSIL but negative colposcopy (absence of colposcopic lesion or positive colposcopy but subsequent negative biopsy) who do not require treatment (therefore as per the recommendation of the SICPCV go to follow-up with HPV testing at 12 months).

Exclusion Criteria:

* Women who have been vaccinated for HPV.
* Patients who have undergone cervical treatments for preneoplastic pathology.
* Patients with High-Grade Squamous Intraepithelial Lesion (HSIL) cytological result who on histological examination after biopsy need treatment according to the SICPCV 2019 recommendations.
* Hypersensitivity to one or more components of the product.
* Patients being treated with antibiotic, immunomodulatory and immunosuppressive therapies.
* Patients with immune system or neoplastic pathologies being treated with chemotherapy
* Patients who are pregnant, breastfeeding, or planning to become pregnant in the next 6 months.

References

Publications (0)

Data not yet available

No reference posted for this study.